CytomX Therapeutics vs Janux Therapeutics
CTMX and JANX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTMX and JANX compare
Janux Therapeutics is the larger company, worth 1.6 times as much as CytomX Therapeutics ($695M against $445M).
Janux Therapeutics grew revenue faster over the last twelve months (133% versus −87.7% for CytomX Therapeutics).
Janux Therapeutics keeps more of each dollar of sales as profit, with a net margin of −429% compared with −609% at CytomX Therapeutics.
Janux Therapeutics scores higher on the StockData Score (12 against 8 for CytomX Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTMX | JANX |
|---|---|---|
| Size and price | ||
| Market cap | $445M | $695M |
| Share price | $2.04 | $11.37 |
| Change, 1 year | −51.8% | −60.1% |
| Change, 5 years | −72.2% | −36.4% |
| Beta (5Y) | 1.59 | 1.60 |
| Employees | 69 | 109 |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 31.7× | 29.8× (better) |
| P/B | 1.6× | 0.8× (better) |
| FCF yield | −11.5% | −7.8% (better) |
| Fair value | – | $16.54 |
| Margin of safety | – | 31.3% |
| Growth | ||
| Revenue growth (TTM) | −87.7% | 133% (better) |
| Revenue growth, 5Y average | 2.2% | – |
| Net income growth (TTM) | −405% | – |
| EPS growth (TTM) | −215% | – |
| Profitability | ||
| Operating margin | −676% | −599% (better) |
| Net margin | −609% | −429% (better) |
| FCF margin | −364% | −233% (better) |
| Return on equity | −43.6% | −10.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.82 | 17.69 (better) |
| Altman Z-score | 0.58 | 5.85 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | −55.0% | – |
| Shareholder yield | −55.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 101% |
| Held by insiders | 1.5% | 21.3% |
| Insider net buying, 12 months | −$1.2M | −$457K (better) |
| Short interest, % of float | 21.1% | 11.1% |
Go deeper
- CTMX stock overview
- CTMX income statement
- CTMX valuation and score
- JANX stock overview
- JANX income statement
- JANX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.